UK biotech's VC fundraising revival Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

Mon T W Th F 20 July, 2026

J.P. Morgan was the right banking team for Montara Therapeutics. Founder Nicholas Hertz trusted the team’s life sciences expertise, security, and support to focus on what mattered most. sponsored by J.P.Morgan

presented by HIV Ends Here: In­side Vi­iV Health­care’s Sin­gu­lar Mis­sion

news Bristol Myers says it will build pharma's 'most powerful' AI supercomputer with Nvidia UK biotech VC funding rebounds and reaches record high Midsized biotechs take case against CMS' GLOBE and GUARD models to White House

Jul 30 1:00 pm ET Accelerating Phase 1 decisions with liquid biopsy: From early signals to actionable insights sponsored by GUARDANT Aug 19 1:00 pm ET From pilots to production: AI across R&D, safety, regulatory, and clinical sponsored by IBM

Associate Director / Director, Preclinial Development - Immunology Terray Therapeutics, Inc. Monrovia, CA, USA Senior Director, Licensing Officer Bayer Cambridge, MA, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

The most differentiated science stays out of public view. This September, the Endpoints newsroom reveals the 11 private companies worth watching, live at the State Room in Boston. See the list first, reserve your spot and save with the early bird rate.

ENDPOINTS PHARMA Updated: BlossomHill and Latigo join flourishing IPO queue with cancer, pain drugs Celcuity got its cancer drug approved. Then its stock dipped Peer Review Zealand Pharma gets its US marketing leader from Lilly; Bexorg turns to Biohaven for CSO hire

in case you missed it 1. Can the shingles vaccine prevent Alzheimer’s? GSK has a big study to find out 2. News Briefing Dimerix buys a kidney injury drug; Arpeggio appears to be winding down 3. GSK drops Phase 3 chronic cough drug in a blow to $2B Bellus Health buyout 4. Mirador unveils a piece of pipeline with drug from Kira to rival troubled Tavneos 5. CRISPR gets a power boost from AI-designed ‘molecular scissors’ 6. AstraZeneca highlights rare diseases in $80bn revenue push